CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 123
- Registration Number
- NCT02452476
- Locations
- 🇺🇸
Martha Naylor, Greenville, North Carolina, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 428
- Registration Number
- NCT02432833
- Locations
- 🇮🇹
Chiesi farmaceutici Spa, Parma, Italy
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001
- Conditions
- Interventions
- First Posted Date
- 2015-03-12
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 48
- Registration Number
- NCT02386761
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, UK, United Kingdom
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 50
- Registration Number
- NCT02359292
- Locations
- 🇧🇪
SGS CPU Antwerpen, Antwerpen, Belgium
Efficacy of LAMA Added to ICS in Treatment of Asthma
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 98
- Registration Number
- NCT02296411
- Locations
- 🇩🇪
Chiesi Clinical Trial Site 0202, Leipzig, Germany
🇩🇪Chiesi Clinical Trial Site 0206, Magdeburg, Germany
🇳🇱Chiesi Clinical Trial Site 0404, Assen, Netherlands
Drug-drug Interaction Study of CHF5993 With Cimetidine
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 25
- Registration Number
- NCT02287272
- Locations
- 🇧🇪
Life Science Services SGS Belgium NV, Antwerp, Belgium
Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2014-07-14
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 100
- Registration Number
- NCT02189577
- Locations
- 🇩🇪
Site 2020 - Pulmonary Research Institute at Hospital Grosshansdorf, Großhansdorf, Germany
🇧🇬Chiesi Clinical Trial Site 1015, Sofia, Bulgaria
🇧🇬Chiesi Clinical Trial Site 1013, Troyan, Bulgaria
A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler
- Conditions
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 60
- Registration Number
- NCT02148120
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
🇬🇧Hammersmith Medicines Research, London, United Kingdom
🇬🇧Respiratory Clinical Trials, Hearth Lung Centre, London, United Kingdom
Triple in Asthma Dose Finding
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 211
- Registration Number
- NCT02127866
- Locations
- 🇧🇬
Chiesi Clinical Trial Site 0103, Stara Zagora, Bulgaria
🇧🇬Chiesi Clinical Trial Site 0106, Sevlievo, Bulgaria
🇩🇪Chiesi Clinical Trial Site 0208, Berlin, Germany
AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)
- Conditions
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 872
- Registration Number
- NCT02123667
- Locations
- 🇧🇷
Prof. Dr. Alberto Cukier, São Paulo, Brazil
🇺🇸Chiesi Clinical Trial Site #0503, Denver, Colorado, United States
🇺🇸Chiesi Clinical Trial Site #0502, Durham, North Carolina, United States